alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26,076–26,100 of 27,146 studies marked Peer-reviewed (page 1044 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Sheng li xue bao : [Acta physiologica Sinica] 2005-02-01

Hyperphosphorylated microtubule-associated protein tau is the major protein component of neurofibrillary tangles in the brain of patients with Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Expression of Osteoarthritis Marker YKL-39 is Stimulated by Transforming Growth Factor Beta (TGF-beta) and IL-4 in Differentiating Macrophages

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Biomarker insights 2008-02-14

YKL-39 is a Glyco_18 domain containing chitinase-like protein which is currently recognized as a biomarker for the activation of chondrocytes and the progress of the osteoarthritis in human. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Dementia and geriatric cognitive disorders 2011-11-03

Detection of cerebrospinal fluid (CSF) biomarker deviations improve prediction of progression from mild cognitive impairment (MCI) to dementia. 4 key findings →

Participants: 161 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebrospinal fluid tau protein is increased in neurosyphilis: a discrimination from syphilis without nervous system involvement?

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Sexually transmitted diseases 2007-04-01

The objective of this study was to investigate the levels of tau protein in neurosyphilis. 4 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Hypercapnic and Hypoxic Respiratory Response During Wakefulness and Sleep in a Streptozotocin Model of Alzheimer's Disease in Rats

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01

Besides the typical cognitive decline, patients with Alzheimer's disease (AD) develop disorders of the respiratory system, such as sleep apnea, shortness of breath, and arrhythmias. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Biomarkers with Plasma Amyloid β and Tau Protein Assayed by Immunomagnetic Reduction in Patients with Amnestic Mild Cognitive Impairment and Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Acta neurologica Taiwanica 2022-06-01

This review addresses recent developments in the analyses of plasma amyloid beta (Aβ) and total tau (t-tau) protein levels as biomarkers for discriminating amnestic mild cognitive impairment (aMCI) from Alzheimer disease (AD), using immunomagnetic reduction (IMR). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Neurologia (Barcelona, Spain) 2013-08-20

The goals of this study were to compare the early diagnostic utility of Alzheimer disease biomarkers in the CSF with those in brain MRI in conditions found in our clinical practice, and to ascertain the diagnostic accuracy of both techniques used together. 4 key findings →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease]

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Lakartidningen 2024-05-31

Technical developments have paved the way for the development of ultrasensitive analytical methods that allow for precise quantification of brain-specific proteins in blood samples. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer’s disease progression that reinforces the 2018 NIA-AA research framework

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of Alzheimer's disease : JAD 2018-10-15

The 2018 NIA-AA research framework proposes a classification system with beta- A myloid deposition, pathologic T au, and n eurodegeneration (ATN) for the diagnosis and staging of Alzheimer’s Disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

What have we learned from past failures of investigational drugs for Alzheimer's disease?

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Expert opinion on investigational drugs 2021-12-20

In the last 15 years, huge efforts against Alzheimer's disease (AD) with drugs targeting β-amyloid (Aβ) and tau have produced poor clinical results. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Expert opinion on emerging drugs 2024-01-12

Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

ACCESS TO NEIGHBORHOOD AMENITIES AND RISK OF INSTITUTIONALIZATION AMONG PERSONS WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Innovation in Aging 2023-12-01

This may be due to caregiving challenges associated with the behavioral symptoms PWD exhibit and their reduced capacities to perform daily tasks. 5 key findings →

Participants: 3,366 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The “Rising Tide” of dementia in Canada

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 2015-06-17

The prevalence of dementia was estimated at 44.4 million people worldwide in 2013, and in the absence of any significant new scientific discovery, prevalence rates are estimated to increase to 75.6 million in 2030 and 135.5 million in 2050.1 Alzheimer’s disease is the most common irreversible form of dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Interventions to optimize prescribing for older people in care homes

✓ Peer-reviewed alzhub usefulness score 34 out of 100. International Journal of Nursing Practice 2019-07-09

In 2017, the United Nations reported that the world's population aged 60 years and over was 962 million people, over twice as many older persons than was reported in 1980. 1 key finding →

Participants: 1,000 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Unexpected Suicidality in an Older Individual in an Emergency Department

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of the American Geriatrics Society 2013-06-01

On supplementary questioning, he revealed multiple recent social stressors, including the 1-year anniversary of his partner's death and an impending eviction from his home with the loss of his beloved garden. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

HEALTH SYSTEM ADOPTION OF COMMUNITY-BASED EXERCISE FOR OLDER ADULTS TO ADDRESS LONELINESS AND SOCIAL ISOLATION

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Innovation in Aging 2024-12-01

Research participants enrolled in Falls Prevention EBPs reported decreased levels of loneliness and social isolation and were referred by physicians, social workers, and pharmacists using an order in the electronic medical record (EMR). 2 key findings →

Participants: 382 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed